Alex Pokov

752 total citations
16 papers, 595 citations indexed

About

Alex Pokov is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine and Hematology. According to data from OpenAlex, Alex Pokov has authored 16 papers receiving a total of 595 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Cardiology and Cardiovascular Medicine, 6 papers in Internal Medicine and 5 papers in Hematology. Recurrent topics in Alex Pokov's work include Antiplatelet Therapy and Cardiovascular Diseases (12 papers), Venous Thromboembolism Diagnosis and Management (6 papers) and Platelet Disorders and Treatments (4 papers). Alex Pokov is often cited by papers focused on Antiplatelet Therapy and Cardiovascular Diseases (12 papers), Venous Thromboembolism Diagnosis and Management (6 papers) and Platelet Disorders and Treatments (4 papers). Alex Pokov collaborates with scholars based in United States, Norway and Canada. Alex Pokov's co-authors include Victor L. Serebruany, Alex I. Malinin, V. L. Serebruany, Dan Atar, Mohamed H. Kotob, Dianne E. Schwartz, Ehtisham Mahmud, Kenneth A. Schwartz, Anthony DeFranco and Daniel F. Hanley and has published in prestigious journals such as Stroke, The American Journal of Cardiology and Neuropsychopharmacology.

In The Last Decade

Alex Pokov

16 papers receiving 580 citations

Peers

Countries citing papers authored by Alex Pokov

Since Specialization

Citations

This map shows the geographic impact of Alex Pokov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alex Pokov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alex Pokov more than expected).

Fields of papers citing papers by Alex Pokov

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alex Pokov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alex Pokov. The network helps show where Alex Pokov may publish in the future.

Co-authorship network of co-authors of Alex Pokov

This figure shows the co-authorship network connecting the top 25 collaborators of Alex Pokov. A scholar is included among the top collaborators of Alex Pokov based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alex Pokov. Alex Pokov is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Clopidogrel, prasugrel, ticagrelor or vorapaxar in patients with renal impairment: do we have a winner? 2015 ·Expert Review of Cardiovascular Therapy ·Victor L. Serebruany, Aleš Tomek, Alex Pokov, (unknown)	6
2	Effect of Aliskiren and Valsartan Combination Versus Aliskiren Monotherapy on Hemostatic Biomarkers in Hypertensive Diabetics 2013 ·American Journal of Therapeutics ·Victor L. Serebruany, Alex Pokov, Dániel Aradi, (unknown), James J. DiNicolantonio, Nodar Kipshidze, Dan Atar	1
3	Disbalance between mortality and non-fatal vascular events in the CHAMPION-PHOENIX trial: The cangrelor efficacy challenge 2013 ·Thrombosis and Haemostasis ·Alex Pokov, Seth D. Fortmann, James J. DiNicolantonio, Victor L. Serebruany	6
4	Early Impact of Prescription Omega-3 Fatty Acids on Platelet Biomarkers in Patients with Coronary Artery Disease and Hypertriglyceridemia 2011 ·Cardiology ·Victor L. Serebruany, Michael Miller, Alex Pokov, Donald Lynch, Jesper K. Jensen, Jonas Hallén, Dan Atar	22
5	A Randomized Trial of Aspirin at Clinically Relevant Doses and Nitric Oxide Formation in Humans 2010 ·Journal of Cardiovascular Pharmacology and Therapeutics ·Charles H. Hennekens, (unknown), Alex Pokov, Scott Hetzel, David L. DeMets, Victor L. Serebruany, H. Schröder	23
6	Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: A randomized, single-blind, 30-day trial 2008 ·Clinical Therapeutics ·Victor L. Serebruany, Alex I. Malinin, Alex Pokov, Daniel F. Hanley	21
7	Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: The PLavix Use for Treatment Of Diabetes (PLUTO-Diabetes) Trial 2007 ·American Heart Journal ·Victor L. Serebruany, Alex I. Malinin, Alex Pokov, Gregory W. Barsness, Daniel F. Hanley	25
8	Antiplatelet Properties of Escitalopram in Patients with the Metabolic Syndrome: A Dose-Ranging In Vitro Study 2007 ·Neuropsychopharmacology ·Dan Atar, Alex I. Malinin, Alex Pokov, Louis van Zyl, Nancy Frasure‐Smith, François Lespérance, Victor L. Serebruany	19
9	Effect of Statins on Platelet PAR-1 Thrombin Receptor in Patients With the Metabolic Syndrome (From the PAR-1 Inhibition by Statins [PARIS] Study) 2006 ·The American Journal of Cardiology ·Victor L. Serebruany, Michael Miller, Alex Pokov, Alex I. Malinin, David R. Lowry, Jean-François Tanguay, Charles H. Hennekens	58
10	Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12® rapid analyzer: The VERIfy Thrombosis risk ASsessment (VERITAS) study 2006 ·Thrombosis Research ·Alex I. Malinin, Alex Pokov, (unknown), Anthony DeFranco, Kenneth A. Schwartz, Dianne E. Schwartz, Ehtisham Mahmud, Dan Atar, Victor L. Serebruany	184
11	Escitalopram, but Not Its Major Metabolites, Exhibits Antiplatelet Activity in Humans 2006 ·Journal of Clinical Psychopharmacology ·Dan Atar, Alex I. Malinin, (unknown), Alex Pokov, Louis van Zyl, Jean-François Tanguay, François Lespérance, Victor L. Serebruany	26
12	Validation of a VerifyNow-P2Y12 cartridge for monitoring plateletinhibition with clopidogrel 2006 ·Methods and Findings in Experimental and Clinical Pharmacology ·(unknown), Alex Pokov, (unknown), Mohamed H. Kotob, V. L. Serebruany	120
13	Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: Hitting the TARGET in the TENACITY trial? 2006 ·Thrombosis Research ·Victor L. Serebruany, Alex I. Malinin, Alex Pokov, Umesh K. Arora, Dan Atar, Dominick J. Angiolillo	7
14	Dipyridamole Decreases Protease-Activated Receptor and Annexin-V Binding on Platelets of Poststroke Patients with Aspirin Nonresponsiveness 2005 ·Cerebrovascular Diseases ·Victor L. Serebruany, Alex I. Malinin, Wendy Ziai, Dan Atar, Alex Pokov, Bernd Jilma, Daniel F. Hanley	9
15	Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial 2005 ·American Heart Journal ·Victor L. Serebruany, Alex Pokov, Alex I. Malinin, Christopher M. O’Connor, Deepak L. Bhatt, Jean-François Tanguay, David C. Sane, Charles H. Hennekens	18
16	Effects of Clopidogrel and Aspirin in Combination Versus Aspirin Alone on Platelet Activation and Major Receptor Expression in Patients After Recent Ischemic Stroke 2005 ·Stroke ·Victor L. Serebruany, Alex I. Malinin, Wendy Ziai, Alex Pokov, Deepak L. Bhatt, Mark J. Alberts, Daniel F. Hanley	50

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact